6550 Polaris Pharmaceuticals-KY

Release Date: July 2, 2026 Statement Date: July 1, 2026 Statement Time: 17:00:15 Company Code: 6550 Company Name: Polaris Pharmaceuticals-KY Purpose: Announcement of commitments made by the company upon application for stock listing and the subsequent implementation status. Applicable Clause: Clause 51 Factual Date: July 1, 2026

1. Factual Date: July 1, 2026 2. Company Name: Polaris Pharmaceuticals Group Co., Ltd. 3. Relationship with Company (Please specify '本公司' or 'Subsidiary'):本公司 (Our Company) 4. Cross-shareholding Ratio: Not applicable 5. Reason for Occurrence: In accordance with the letter issued by the Taiwan Stock Exchange Corporation on March 25, 2022 (No. 1111700849), the commitments made by the company at the time of its initial stock listing are as follows:

(a) Disclosure in the special notes section of the public offering memorandum regarding the following matters: 1. The company engages in the research and manufacturing of biopharmaceutical new drugs, including the sources of core technologies, patent protection, development progress of each new drug, market competitiveness, potential risks, and mitigation measures. 2. Since 2019, the company has entered the Contract Development and Manufacturing Organization (CDMO) business, and must disclose its development plans, competitive advantages, expected customer base, potential risks, and mitigation strategies. 3. Both new drug development and CDMO operations require substantial capital. The company must disclose future funding needs, financial planning, potential operational liquidity risks, and mitigation measures.

(b) Extend the period for shares deposited in the Central Depository to three years, with only one-third eligible for withdrawal after each full year from the commencement of trading.

(c) Delete Article 42.1 of the Articles of Incorporation regarding independent directors convening shareholder meetings, prior to listing.

6. Mitigation Measures: As of July 1, 2026, the company's implementation status is as follows:

(a) The relevant content has been appropriately disclosed in the public offering memorandum for 'Public Offering of New Shares via Cash Capital Increase Prior to Listing,' published in May 2022. Refer to the Public Information Observation Station.

(b) The deposit period for shares in the Central Depository has been extended to three years, with one-third eligible for withdrawal after each full year from the commencement of trading.

(c) The amendment to the Articles of Incorporation was approved at the shareholders' meeting held on June 2, 2022.

7. Other Matters to be Disclosed: New drug development involves long timelines, high investment costs, and no guarantee of success, which may expose investors to risks. Investors are advised to make careful judgments and invest prudently.